ADA and B-cell non-Hodgkin lymphoma: Others testing the CD22‐targeted iTox IgG‐RFB4‐SMPT‐dgA in patients with B‐cell lymphoma have also observed no difference in ADA formation between bolus and continuous infusion regimens.41, 42, 43